Coumarin-Benzoimidazole Derivatives Show Potential for Being Developed into Novel α-Glucosidase Inhibitors for Type-2 Diabetes Mellitus Management

by Shilpi Aggarwal, PhD, Freelance Writer
A March 28, 2024 article in Nature Scientific Reports describes a successful study on the design, synthesis, and evaluation of novel coumarin-linked 2-phenylbenzimidazole derivatives as potent novel α-glucosidase inhibitors. The open-access article is titled “Coumarin Linked to 2-Phenylbenzimidazole Derivatives As Potent α-Glucosidase Inhibitors.” α-glucosidase inhibitors are a group of antidiabetic drugs used for the management of type-2 diabetes mellitus. They act by inhibiting α-glucosidase, a hydrolase enzyme that is found in the intestinal cells and is responsible for breaking down complex carbohydrates into absorbable monosaccharides, including glucose. The inhibitory effect of α-glucosidase inhibitors decelerates the breakdown of complex carbohydrates, resulting in decreased glucose absorption and a reduced glycemic response post meals. Acarbose is the most widely researched and used drug in this category. However, it exhibits several side effects such as abdominal pain, bloating, and diarrhea in patients.
Login Or Register To Read Full Story